Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.6.417

Budesonide Microemulsions for Enhancing Solubility and Dissolution Rate  

Piao, Hong-Mei (College of Pharmacy and Research Institute for Pharmaceutical Sciences, Seoul National University)
Cho, Hyun-Jong (College of Pharmacy and Research Institute for Pharmaceutical Sciences, Seoul National University)
Oh, Eui-Chaul (STH Pharm Inc)
Chung, Suk-Jae (College of Pharmacy and Research Institute for Pharmaceutical Sciences, Seoul National University)
Shim, Chang-Koo (College of Pharmacy and Research Institute for Pharmaceutical Sciences, Seoul National University)
Kim, Dae-Duk (College of Pharmacy and Research Institute for Pharmaceutical Sciences, Seoul National University)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.6, 2009 , pp. 417-422 More about this Journal
Abstract
Budesonide belongs to Class II in the Biopharmaceutics Classification System (BCS) for its high permeability and poor aqueous solubility. The purpose of this study was to improve the solubility and dissolution rate of budesonide using an o/w microemulsion system in order to develop a nasal formulation. Based on the results of the solubility study and pseudo ternary phase diagrams, microemulsions of about 80 nm in mean diameter were formulated using isopropyl myristate and Labrasol$^{(R)}$ as an oil phase and a surfactant, respectively. Solubility of budesonide in the microemulsions increased up to 6.50 mg/mL, which is high enough for a nasal formulation. In vitro release profiles of budesonide significantly increased from the microemulsions compared to that of the budesonide powder. These results suggest that the microemulsions of budesonide could further be developed into a clinically useful nasal formulation.
Keywords
Budesonide; Microemulsion; Solubilization; In vitro release;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. Divya, S. Elizabeth and K. Deepak, Allergic Rhinitis, Clin. Pediatr., 46, 401-407 (2007).   DOI   ScienceOn
2 H.K. John, Allergic rhinitis - Current pharmacotherapy, Otolaryngol. Clin. N. Am., 41, 347-358 (2008).   DOI   ScienceOn
3 C. LaForce and N.C. Raleigh, Use of nasal steroids in managing allergic rhinitis, J. Allergy Clin. Immunol., 103, S388-394 (1999).   DOI   ScienceOn
4 H. Derendorf and E.O. Meltzer, Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications, Allergy, 63, 1292-1300 (2008).   DOI   ScienceOn
5 K. Deventer, P. Mikulcikova, H. Van Hoecke, P. Van Eenoo and F.T. Delbeke, Detection of budesonide in human urine after inhalation by liquid chromatography–mass spectrometry, J. Pharm. Biomed. Anal., 40, 423-428 (2006).   DOI   ScienceOn
6 S. Edsbacker, P. Andersson, C. Lindberg, A. Ryrfeldt and A. Thalen, Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids, Drug Metab. Dispos., 15, 412-417 (1987).
7 J.S. Stanley and C. Denver, Pharmacokinetics of intranasal corticosteroids, J. Allergy Clin. Immunol., 108, S26-31 (2001).   DOI   ScienceOn
8 M.A. Lopez-Quintela, C. Tojo, M.C. Blanco, L. Garcia Rio and J.R. Leis, Microemulsion dynamics and reactions in microemulsions, Curr. Opin. Colloid Interface Sci., 9, 264-278 (2004).   DOI   ScienceOn
9 A. Morgan, G. Lennart and W. Per, Nasal treatment with a microemulsion reduces allergenchallenge-induced symptoms and signs of allergic rhinitis, Acta Otolaryngol., 128, 666-669 (2008).   DOI   ScienceOn
10 Z. Hu, R. Tawa, T. Konishi, N. Shibata and K. Takada, A novel emulsifier, labrasol, enhances gastrointestinal absorption of gentamicin, Life Sci., 69, 2899–2910 (2001).
11 N. Chidambaram and D.J. Burgess, A novel in vitro release method for submicron sized dispersed systems, AAPS Pharm. Sci., 1, E11 (1998).   DOI
12 L. Djekic and M. Primorac, The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides, Int. J. Pharm., 352, 231-239 (2008).   DOI   ScienceOn
13 M.I. Ugwoke, R.U. Agu, N. Verbeke and R. Kinget, Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives, Adv. Drug Deliv. Rev., 57, 1640-1665 (2005).   DOI   ScienceOn
14 K. Danjo, F. Higuchi and A. Otsuka, Release of lidocaine from polymer film dosage forms, Chem. Pharm. Bull., 43, 1759-1763 (1995).   DOI   ScienceOn
15 T. Furubayashi, D. Inoue, A. Kamaguchi, Y. Higashi and T. Sakane, Influence of formulation viscosity on drug absorption following nasal application in rats, Drug Metab. Pharmacokinet., 22, 206-211 (2007).   DOI   ScienceOn
16 A.H. Anwar, Intranasal drug delivery, Adv. Drug Deliv. Rev., 129, 39-49 (1998).
17 T. Selcan, O. Erte and O. Yekta, Nasal route and drug delivery systems, Pharm. World Sci., 26, 137-142 (2004).   DOI   ScienceOn